Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia
- PMID: 28975435
- DOI: 10.1007/s10654-017-0318-z
Life course body mass index and risk and prognosis of amyotrophic lateral sclerosis: results from the ALS registry Swabia
Abstract
Weight loss appears as a strong predictor of survival of patients with amyotrophic lateral sclerosis, yet no data are currently available to describe the life course history of pre-diagnostic body mass index (BMI) in these patients. 393 ALS cases (mean age: 65.8 years, 57.3% men) and 791 controls matched by age and sex from a population-based case-control study of the ALS Registry Swabia were analyzed. Differences of BMI change in cases and controls over time were modeled using a multilevel additive model. In addition, survival in ALS cases by BMI change was modeled using an accelerated failure time model adjusted for prognostic factors. In ALS cases, BMI was consistently higher than in controls in the 20-70 years before the interview. Conditional logistic regression revealed an odds ratio of 1.05 (95% confidence interval (CI) 1.00-1.11, p = 0.041) per 1 kg/m2 higher BMI 35-45 years before interview. However, a sharp decrease was evident in the BMI of ALS cases about 10 years before disease onset. Moreover, weight loss was strongly associated with shorter survival in ALS patients. Illustrating this, patients with stable weight showed a median survival time of 22.1 (95%-CI 19.2-25.0) months, as compared to 13.4 (95%-CI 10.5-16.3) months for patients with weight loss of 2.5 kg/m2 over the last 3 months before the interview. Thus, alterations in body weight are present in ALS patients already decades before clinical manifestation of ALS, while weight loss precedes motor symptoms of several years and is associated with poor prognosis.
Keywords: Amyotrophic lateral sclerosis; Body mass index; Hypermetabolism; Prognostic factor; Risk factor; Weight change; Weight loss.
Similar articles
-
Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry.J Neurol. 2023 Jun;270(6):3082-3090. doi: 10.1007/s00415-023-11630-4. Epub 2023 Feb 28. J Neurol. 2023. PMID: 36853389 Free PMC article.
-
Association of Serum Retinol-Binding Protein 4 Concentration With Risk for and Prognosis of Amyotrophic Lateral Sclerosis.JAMA Neurol. 2018 May 1;75(5):600-607. doi: 10.1001/jamaneurol.2017.5129. JAMA Neurol. 2018. PMID: 29482216 Free PMC article.
-
Cystatin C based estimation of chronic kidney disease and amyotrophic lateral sclerosis in the ALS registry Swabia: associated risk and prognostic value.Sci Rep. 2023 Nov 10;13(1):19594. doi: 10.1038/s41598-023-46179-9. Sci Rep. 2023. PMID: 37949878 Free PMC article.
-
Systematic review of the prognostic role of body mass index in amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):356-367. doi: 10.1080/21678421.2019.1587631. Epub 2019 Apr 1. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 30931632
-
[Epidemiology of amyotrophic lateral sclerosis].Rev Neurol (Paris). 2009 Aug-Sep;165(8-9):627-40. doi: 10.1016/j.neurol.2009.04.004. Epub 2009 Jun 13. Rev Neurol (Paris). 2009. PMID: 19524991 Review. French.
Cited by
-
Skeletal Muscle in ALS: An Unappreciated Therapeutic Opportunity?Cells. 2021 Mar 2;10(3):525. doi: 10.3390/cells10030525. Cells. 2021. PMID: 33801336 Free PMC article. Review.
-
Effect of body mass index on survival after spinal cord injury.Front Neurol. 2024 Jan 26;14:1269030. doi: 10.3389/fneur.2023.1269030. eCollection 2023. Front Neurol. 2024. PMID: 38344110 Free PMC article.
-
Association of blood lipids with onset and prognosis of amyotrophic lateral sclerosis: results from the ALS Swabia registry.J Neurol. 2023 Jun;270(6):3082-3090. doi: 10.1007/s00415-023-11630-4. Epub 2023 Feb 28. J Neurol. 2023. PMID: 36853389 Free PMC article.
-
Nutritional and metabolic factors in amyotrophic lateral sclerosis.Nat Rev Neurol. 2023 Sep;19(9):511-524. doi: 10.1038/s41582-023-00845-8. Epub 2023 Jul 27. Nat Rev Neurol. 2023. PMID: 37500993 Review.
-
Potential Applications for Growth Hormone Secretagogues Treatment of Amyotrophic Lateral Sclerosis.Curr Neuropharmacol. 2023;21(12):2376-2394. doi: 10.2174/1570159X20666220915103613. Curr Neuropharmacol. 2023. PMID: 36111771 Free PMC article.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous